Seizure Control as a New Metric in Assessing Efficacy of Tumor Treatment in Patients With Low Gra… (NCT04553757) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Seizure Control as a New Metric in Assessing Efficacy of Tumor Treatment in Patients With Low Grade Glioma
United States100 participantsStarted 2020-07-08
Plain-language summary
This study investigates how seizures can vary over time with changes in low grade gliomas and its treatments. This study may help doctors find symptoms or triggers of seizures earlier than normal, and ultimately earlier care or treatment for seizures.
Who can participate
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adult patients
* Primary brain tumors (separated by World Health Organization \[WHO\] grade I-IV)
* History of seizures secondary to brain tumor
* On tumor directed treatment
* Magnetic resonance imaging (MRI) within 2 weeks of clinic visit where seizure assessment takes place
Exclusion Criteria:
* Patients without seizures
* Patients with intracranial lesions other than primary brain tumor
* Patients not undergoing tumor directed treatment
* Absence of recent (within 2 weeks) MRI
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This study is looking at whether seizure control can be used as a way to measure how well a tumor treatment is working — does my own seizure history make me a good candidate to discuss this kind of approach with my care team?
2Since this trial is 'active not recruiting,' it's no longer enrolling new patients — are there similar studies still open that are looking at seizure frequency as a sign of low-grade glioma response to treatment?
3The trial tracks both the rate of change in seizure frequency and tumor status together — what does my doctor currently use to judge whether my tumor treatment is working, and could seizure patterns be a meaningful signal in my specific case?
4Low-grade gliomas can sometimes be managed with watchful waiting rather than immediate treatment — given what this study is examining, how would my doctor weigh seizure activity as a factor when deciding whether or not to start or change my treatment?
5Since this is listed as Phase NA, meaning it's likely an observational or data-collection study rather than a test of a new drug or procedure, what would my doctor say about how findings from this kind of study might influence real treatment decisions for someone in my situation?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.